RESEARCH PAPER

Development Of Biodegradable Polymeric Implants For Sustained Release Of Small-Molecule Or Peptide Drugs.

Dr. Smriti Dewangan[1], Dr. Prabha Modi[2], Dinesh V[3], Prof.(Dr.) Biswabandita Kar[4], Dr. Pravat Ranjan Dixit[5], Sachin Shivam[6], Gopal Dilip Wagh[7]

[1]. Amity institute of Pharmacy, Amity University, Raipur, Chhattisgarh
Email Id: smritidewangan88@gmail.com
Orcid Id: 0000-0002-5429-9883
[2]. Assistant Professor, Department of Applied Science, Faculty of Engineering and Technology, Parul University
Email Id: prabharawat.modi@gmail.com
Orcid Id: 0000-0001-9082-9792
[3]. Assistant Professor, Department of Chemical Engineering, Vel Tech High Tech Dr. Rangarajan Dr. Sakunthala Engineering College
Mail Id: dineshvishwanathan2210@gmail.com
[4]. Professor of Chemistry, KIIT Deemed to be University, Bhubaneswar
[5]. Lecturer in Chemistry, Chitalo Degree College, Jajpur(Under Utkal University, Bhubaneswar), Odisha, Pin-755062
E-mail Id: pravatdixit@gmail.com
Orcid id- 0000-000-5984-01117
[6]. M. Pharm pharmacology SCHOOL OF PHARMACY, LNCT UNIVERSITY, BHOPAL, (M.P)
Email Id: shivamsachin49@gmail.com
[7]. Department of Physics, MGSM's Dadasaheb Dr. Suresh G. Patil College, Chopda.
Email ID- wagha2541995@gmail.com

ABSTRACT
immersible polymeric implants have turned out to be a viable approach to sustained and graduated drug delivery, especially to a long-term regimen. The study is aimed at creating and testing biodegradable polymer-based implant systems that are expected to deliver small-molecule drugs and peptide therapeutics in a sustained manner. The main aim was to determine the effects of polymer choice, fabrication methods and drug properties about releasing kinetics, stability and biocompatibility. Solvents based and melt-processing techniques were used to make the implants using established biodegradable polymers, and then methodical drug loading and physicochemical characterisation performed. In vitro release experiments were done to determine release profiles, and the degradation behaviour and biocompatibility were determined using standard analytical and biological assays. The findings showed that the composition and the structure of the implants are crucial factors that can regulate the rate of release, reduce the burst release and retain the integrity of the peptide in the long run..

Keywords: Biodegradable polymers; Polymeric implants; Sustained drug release; Small-molecule drugs; Peptide delivery
How to cite this article: Dewangan S, Modi P, Dinesh V, Kar B, Dixit PR, Shivam S, Wagh GD..; Development Of Biodegradable Polymeric Implants For Sustained Release Of Small-Molecule Or Peptide Drugs...Int J Drug Deliv Technol. 2026; 16(8s): 390-397; DOI: 10.25258/ijddt.16.8s.53
Source of support: Nil.
Conflict of interest: None

INTRODUCTION

1.1 Clinical Need for Long-Acting Drug Delivery

The current clinical practice demands more some drug delivery system that can preserve the therapeutic levels during a longer period. Long term drugs are commonly needed to treat chronic illnesses like cancer, diabetes, hormonal disorders and inflammatory diseases and therefore regular drug exposure is essential to achieving therapeutic success. Traditional modes of drug delivery, especially oral and injectable routes of delivery often do not give sustained levels of drugs resulting in variable plasma concentrations and poor treatment effects.

1.2 Limitations of Conventional Dosage Forms

Oral delivery is also a characteristic that is closely related to low bioavailability because of the metabolism of the first pass, enzymatic degradation, and variable absorption into the gastrointestinal tract. Although injectable therapies are not subject to all these limitations, they typically necessitate frequent administration, thus exposing patients to the risk of discomfort, non-adherence, and clinical complications. The challenges are further increased in drugs whose half-lives are short or therapeutic windows, leading to the need to seek alternative delivery methods that may help to enhance patient adherence and therapeutic effects.

**Author for Correspondence: Dr. Smriti Dewangan*

1.3 Biodegradable Polymeric Implants as an Advanced Solution

The biodegradable polymeric implants have become a promising idea in long term and localized delivery of drugs. Such systems are designed to discharge therapeutic agents at a specific rate but will break down into biocompatible by-products gradually thus avoiding the need to be removed surgically. Polymeric implants minimize administration frequency, minimize systemic exposure and enhance compliance in patients by ensuring that the drug is sustained at the target location. As a result, these types of implantable platforms improve the efficiency of therapy, promote the management of diseases over the long term, and are an innovative solution to modern controlled drug delivery plans of various clinical indications and pharmaceutical use in different countries of the world.

1.4 Distinct Challenges of Small-Molecule and Peptide Therapeutics

Peptide therapeutics and small-molecule drugs pose different formulation and release issues in implantable systems. Small molecules can easily penetrate polymer matrices, with resulting burst release, whereas peptides are susceptible to instability, denaturation and degradation by enzymes. Controlled release at the same time maintaining drug integrity thus involves a fine selection of materials and design of the implants.

1.5 Research Gaps, Aim, and Article Structure

Nevertheless, there are still gaps in the efforts to optimise polymer composition, fabrication and release control of various types of drugs even with the significant progress in this field. This study will solve these challenges by designing biodegradable polymeric implants to deliver small-molecule and peptide drugs in a sustained delivery. The focus is on the realisation on the degradation behaviour of polymers, the implant architectures, and the interactions between the drugs and polymers, which in turn have a cumulative impact on the release kinetics and biocompatibility, which in turn will be key to the rational design of clinically viable long-acting implantable drug delivery systems in future pharmaceutical applications.

2. Literature Review and Theoretical Background

2.1 Biodegradable Polymers in Drug Delivery

Biodegradable polymers are of central importance in the formulation of the implantable drug delivery systems because they break down into non-toxic by-products in the body. The poly(lactic-co-glycolic acid) (PLGA) is one of the most widely researched synthetic polymers since the degradation rate is easily regulated depending on the lactic-to-glycolic ratio [1]. PLGA is degraded by hydrolytic rupture of the ester bonds, which is mainly metabolised to lactic acid and glycolic acid, which are absorbed by the natural biochemical pathway. Poly(lactic acid) (PLA) is less degradable than PLGA, since the material is more hydrophobic and is more crystalline and therefore is applicable in long-lasting drug release.

Another biodegradable polymer is Polycaprolactone (PCL) defined by semi-crystalline values, long degradation curve, typically time-spanning several months or years which is beneficial in prolonging the therapeutic delivery. Besides synthetic polymers, natural polymers like chitosan, gelatin, alginate and collagen have also been of interest because of their natural biocompatibility and bioactivity. Such materials tend to degrade by enzymatic action and can be used to allow cell contacts, but their batch-to-batch variability and lower mechanical strength may limit use in implants. Molecular weight, crystallinity, hydrophobicity, and glass transition temperature are physicochemical characteristics that have a potent effect on polymer degradation behaviour and kinetics of drug release.

The choice of the proper biodegradable polymer is thus very critical to ensure a stable implant performance, mechanical integrity throughout implantation, and prolonged drug release profile, consistent with the clinical needs and patient safety aspects. Developments in future also aim at making polymer blends and copolymers more customizable to adjust the rate of degradation and mechanical behaviour [2]. Improvements in polymer production, such as functionalised and stimuli-responsive biodegradable polymers, give a possibility to make further steps in promoting drug stability and release specificity.

2.2 Polymeric Implant Systems

Long-term and localized drug delivery Polymeric implant systems have been extensively explored as drug delivery platforms. Rod-shaped implants, which are solid (and have simple designs), are the most utilized designs that are easy to fabricate, exhibit mechanical stability, and the release profile can be controlled by polymer degradation and diffusion processes. Such implants find application in hormone therapeutics and oncology, in which prolonged (month-long) levels of drug dose are necessary. Implants loaded with microspheres are a more elaborate system, which entails incorporation of polymeric microspheres inside a solid skeleton to have further control over drug release kinetics. Such a multi-layer design can reduce the initial burst release as well as permit more controlled drug distribution, but it complicates and makes it more expensive to manufacture.

Another valuable category of polymeric systems, also called situ forming implants, are those which are normally delivered in injectable forms and hardens when it meets physiological fluids. These systems provide low invasive delivery and flexibility to non-regular anatomical locations, which has made them quite appealing in the delivery of local therapies. Nonetheless, the in-situ forming implants can be afflicted with aspects of solvent toxicity, erratic hardening, and initial burst out [3]. All designs of implants have benefits and drawbacks based on the process of fabrication, scalability, comfort, and acceptance of the implants by the regulatory authorities. Such parameters as mechanical strength, degradation consistency, and drug loading are the important parameters that determine the performance of implants and clinical translation.

Nevertheless, even with notable advancement, the current implantation systems tend to have issues in reaching a compromise between sustained release, manufacturability, and patient safety, which illustrates the necessity of further improvements in the field of design of implantation and material engineering. New types of implant designs are

actively incorporating new manufacturing methods including three-dimensional printing and microfabrication to enhance structural accuracy and uniformity. The techniques facilitate device-specific implant geometries, optimised drug delivery, and are scalable.

2.3 Challenges in Sustained Delivery of Small-Molecule and Peptide Drugs

There are numerous formulation and biological challenges in the attainment of sustained delivery of small-molecule and peptide drugs with the help of biodegradable polymeric implants. Small-molecule drugs are usually characterized by low molecular weight and high diffusivity, leading to high drug mobility across polymer matrices and high initial burst release. This unregulated release can cause subtherapeutic level in the long run or the danger of toxicity. Conversely, peptide drugs are complex in structure and are by nature unstable so that they are vulnerable to degradation due to hydrolysis, oxidation, and enzyme activity. Peptide integrity has been shown to be a major challenge in the fabrication of the implants and during the release period. Diffusion-controlled and degradation-controlled processes affect the mechanisms working on drug release.

The systems that are dominated by the diffusion process usually release the drugs quickly whereas the degradation-regulated systems use the erosion of the polymer to control the speed of release. It is important to strike an ideal balance between these mechanisms to achieve predictable delivery in the long run. Besides, the degradation of polymers may lead to the development of acidic micro-environment that has adverse impact on the stability of peptides and their biological activity [4]. There are also challenges with immune response which include an implant material and by-products of degradation may lead to inflammation or foreign body reaction potentially changing release behaviour and tissue compatibility. These issues draw attention to the difficulty in developing implantable platforms that can support the unique physicochemical and biological needs of small-molecule and peptide therapeutics.

To solve these problems, it is necessary to select polymers carefully, develop high-level fabrication techniques, and properly consider the release kinetics, stability, and biocompatibility of the entire system to provide a safe and effective sustained drug delivery. The recent studies tend to focus more on allaying these obstacles by polymer buffering methods, surface modification, and protection of the drugs by encapsulation. The use of stabilising excipients and anti-inflammatory agents in the matrix of implants has demonstrated potential in the maintenance of drug activity and lowering of immune responses.

3. Materials and Methods



Figure 1: Biodegradable Polymeric Implant Drug Delivery

3.1 Materials Selection and Polymer Characterisation

The biodegradable polymers were chosen based on biocompatibility, rate of degradation and biodegradables implantable drug delivery. Representative synthetic polymers were poly(lactic -glycolic acid), poly(lactic acid), and polycaprolactone, and chitosan was regarded as a comparator of the natural polymers. Small-molecule and peptide drugs were selected as models to reflect the opposite features of molecular weight, solubility and stability. Gel permeation chromatography and nuclear magnetic resonance spectroscopy were used to verify the polymer molecular weight and composition [5]. Glass transition and melting temperatures were measured using the differential scanning calorimetry technique to measure the processing suitability. X-ray diffraction was used to analyse crystallinity and structural organisation.

Scanning electron microscopy was used to investigate surface morphology and microstructure of fabricated implants. The FTIR spectroscopy was used to analyze the chemical integrity and possible polymer-drug interactions. These characterisation methods gave necessary data on polymer behaviour, drug molecule compatibilities, and predicted degradation characteristics, so that the materials to be used during controlled implant fabrication and sustained drug release testing were selected reasonably.

3.2 Implant Fabrication Techniques

The solvent casting, extrusion and compression moulding techniques were used in the production of polymeric implants to assess how processing method affects the structure and performance of the implants. Solvents casting involved dissolving the polymers in the appropriate organic solvents, thereafter, the drug was added and solvent evaporation was regulated under specified conditions to form homogeneous solid implants. The technique allowed low temperature processing, which was especially significant to preserve peptide stability [6]. The extrusion process was done by heating polymer drug mixtures to temperatures higher than the melting point of the polymer and subjecting the molten substance to pressure to fill a calibrated die to produce cylindrical implants of uniform size. This method enabled processing solvent free and enhanced scalability in case of industrial production.

Compression moulding was a process whereby polymer and drug powders are mixed, and compaction of the mixture is done under controlled pressure and temperature to produce dense implant matrices.

The different fabrication methods were optimised to keep drug degradation to a minimum, distribute drugs homogenously and have high mechanical integrity. The parameters of process like temperature, pressure and mixing time were well controlled to minimize variability. The manufactured implants were then cut and kept in regulated conditions before testing. The comparison of these fabrication methods allowed them to assess their appropriateness to most drug classes and gained an idea of manufacturing factors that could be relevant to clinical translation. Also, a comparison of methods of fabrication brought out trade-offs between scalability, cost, and uniformity of products [7].

3.3 Drug Loading and Encapsulation Efficiency

The drug loading was done by the incorporation of pre-determined values of small-molecule drugs or peptide drugs into polymer matrices during manufacturing. In solvent-based technique, the drugs have been dissolved/dispersed in polymer solutions before casting. In melt-based techniques, the drugs were simply mixed with polymers and then extruded or compressed. The efficiency of encapsulation was evaluated by dissolving or degrading implants under specific conditions and analyzing the content of drugs by established analytical procedures. Small-molecule drugs were analysed using high-performance liquid chromatography and peptide contents were analysed using spectroscopic or chromatographic methods [8]. Assessment of encapsulation efficiency was determined by the actual drug content to the theoretical loading. These measurements were to make reproducibility and comparison of fabrication methods in terms of drug retention and uniformity of loading.

3.4 In Vitro Evaluation and Degradation Studies

In vitro release tests were done by incubating implants in a physiological buffer, at different temperatures and agitation. Samples were taken at programmed times to measure drug released and determine the release kinetics with time. Polymer degradation was measured using mass loss methodology, the reduction in its molecular weight and morphological alterations during the incubation process. The assessment of biocompatibility was done through conventional cytotoxicity assays with the appropriate mammalian cell lines to ascertain cellular viability, attachment, and possible inflammatory reaction to implant materials and degradation by-products [9].

4. Results

4.1 Physicochemical Properties of the Implants

In all formulations, the fabricated polymeric implants were found to have a similar morphology with clearly defined structural attributes. SEM allowed seeing smooth outer surfaces with few visible flaws, and the cross-sectional images showed homogenous drug distribution inside. Mechanical tests revealed that the implants had the desired tensile strength and flexibility to be handled and implanted without fracture. The polycaprolactone formulations exhibited greater mechanical stability than the poly(lactic-co-glycolic acid) and poly(lactic acid) formulations, which were in line with their semi crystalline structure. Differential scanning calorimetry ensured that thermal properties of the polymer remained unchanged after the fabrication, which implied minimal degradation of the polymer during processing. The X-ray diffraction analysis revealed that formulations had different crystalline, which affected the degradation behaviour.

The degradation research revealed that the mass reduced with time, and poly(lactic-co-glycolic acid) implants degrade faster than poly(lactic acid) and polycaprolactone systems. The polymer hydrolysis and relaxation of the matrix increased surface erosion and pore formation with duration of incubation. Molecular weight analysis showed gradual scission of the polymer chains without rapid scission [10]. The overall outcomes show that the morphology of the implants, mechanical integrity and degradation behaviour highly relied on the polymer composition and fabrication technique, which offers a stable physicochemical baseline of the sustained drug release performance evaluation. More so, consistency in dimensions was also observed between batches of fabrication and this is a sign of good fabrication reproducibility. Degradation testing did not show any structural breakdown or cracking.

4.2 Drug Release Profiles

Both small-molecule- and peptide-loaded implants exhibited sustained and controlled release behaviour, as shown by the drug release studies. Formulations of small-molecule drugs demonstrated an initial release rate and a long-lasting release of several weeks. The size of initial release was different according to the type of polymer and fabrication method, poly(lactic-co-glycolic acid) types of implants exhibit greater early release than polycaprolactone systems. After this stage, the release rates became constant and dependent on the properties of polymer degradation and diffusion. The release profiles of peptide loaded implants were slower and more gradual with very little burst release in most formulations.



Figure 2: Sustained Release Profiles of Small-Molecule vs Peptide Drugs

It was explained by the fact that polymer-peptide interactions were stronger and that the diffusivity of

peptides in the polymer matrix was lower. Compared to fabrication techniques, it was demonstrated that solvent-cast implants gave more consistent release profiles of peptides whilst extrusion-based implants gave superior consistency in small-molecule delivery. Accumulating release information showed that polymer composition was a major factor in release duration where polycaprolactone implants had the longest release rates [11]. The kinetics of release analysis revealed diffusion-controlled and degradation-controlled release based on the formulation. Altogether, the findings validated that customized polymer choice and fabrication protocols showed foreseeable, constant delivery of drugs of chemically varied therapeutic agents.

The release profiles also revealed that the principle of controlling drug transport pathways depends on the presence of implant architecture and internal microstructure. More porous implants had a higher release rate whereas denser matrice favored longer diffusion distances and slower diffusion.

4.3 Biocompatibility and Stability Results

The biocompatibility test showed good responses of cells in all the implant combinations. Cytotoxicity tests showed high cell viability after exposure to polymeric materials and by-products of the degradation, in which there was no considerable reduction in cell viability as compared to control samples. Microscopic inspection revealed a normal cell morphology and attachment, which indicated minimum adverse cellular interactions [12]. Indicators of inflammatory response were kept at acceptable levels, which means that there is a possibility of no irritation caused by implants. The products of polymer degradation did not cause any noticeable acute inflammatory changes in the conditions of the in vitro. Peptide-loaded implants were analyzed through stability analysis, and the integrity of the peptides was found to remain intact during the release time. Analytical analysis ensured that there was low peptide degradation/ aggregation, which indicated compatibility between the polymer matrices and sensitive biomolecules. Fabrication/release testing also did not impair chemical stability in small-molecule drugs. All these results point to the fact that the designed biodegradable implants of polymeric nature are biocompatible and can preserve drug stability, which proves the appropriateness of the developed types of biodegradable implants in the context of their use as long-term therapeutic delivery methods.

5. Discussion

5.1 Influence of Polymer Selection on Implant Performance

The findings reveal that the polymer choice has a decisive role in regulating the behaviour of implants especially in the rate of degradation, mechanical stability as well as release of drugs. The more crystalline and hydrophobic polymers including polycaprolactone had slower degradation and longer profiles of release, which is consistent with the goal of the study to attain sustained delivery [13]. Conversely, poly(lactic-co-glycolic acid) formulations were able to degrade faster leading to rapid release, which could prove to be beneficial in cases of short-term therapeutic use. The results agree with the current literature that polymer composition and molecular structure have a direct impact on hydrolytic degradation and diffusion in an implant matrix.

5.2 Impact of Fabrication Techniques on Release Kinetics

The fabrication techniques had a tremendous influence on implant microstructure and hence, drug release behaviour. The solvent casting gave homogeneous matrices that allowed regulated peptide release, presumably because the dispersing drug was dispersed better and there was less thermal strain. Extrusion and compression moulding improved mechanical strength and scalability but brought about variability in release based on the conditions of processing [14]. These findings underscore the need to match production of fabrication methods to drug sensitivity and intended clinical effect. Translational This is because solvent-free methods are better in large-scale production, if it is possible to guarantee release predictability.



Figure 3: Polymer Degradation and Drug Release Mechanism

5.3 Small-Molecule Versus Peptide Drug Delivery

There was evident disparity in small-molecule drug delivery and peptides drug delivery profile in biodegradable polymeric implants. Small-molecule drugs were found to have a greater diffusivity resulting in an initial burst release and diffusion and degradation-driven transport. This is caused by their low molecular weight and weak interactions with the polymer chains as shown by such behaviour. Conversely, the release profiles of peptide drugs were slower and more regulated with reduced mobility of molecules and intermolecular forces in the polymer matrix.

5.4 Translational Relevance and Comparison with Commercial Systems

The developed systems show similar behaviour of sustained release with the added flexibility of material choice and fabrication as compared with the current commercial implant technologies. Biodegradable implants have the benefit of doing away with surgery removal where patient compliance has been enhanced [15]. Scalability and regulatory acceptance are also a priority, but the reproducible physicochemical characteristics and the positive biocompatibility provided in this study are indicative of further development. In general, the results

validate the idea that rational polymer choice and fabrication optimisation are the key elements in the process of promoting biodegradable implant technologies to clinically viable, long-action drug delivery solutions [16].

6. Clinical and Pharmaceutical Implications

Biodegradable polymeric implantation has great clinical and pharmaceutical potential as it can provide long-term and local drug delivery and minimize the necessity of regular and frequent dosage. They are especially useful in the treatment of chronic diseases when therapeutic drug compliance over a long duration is necessary because of their capacity to retain them [17]. Implant-based delivery systems may be used to control such conditions as diabetes, inflammatory disorders, and neurological diseases, deliver a steady dose, and reduce the variability of exposure, which is inherent to other types of dosage.

Biodegradable implants can be used in oncology to provide localised chemotherapy thereby decreasing systemic toxicity and enhancing tumour site targeting. Another known use of the long-acting implants to enhance compliance and treatment effectiveness is hormone therapies, including contraceptive and endocrine therapy. Implantable delivery platforms that preserve sensitive biomolecules and permit controlled release can also be of benefit to peptide-based treatments which are usually constrained by low stability and half-lives.

Regulatively, biodegradable implants are beneficial because they do not require surgical removal, and thus the procedure would be less risky, as well as less of a burden to the healthcare system [18]. Nevertheless, uniform quality in manufacturing, reproducible release characteristics and full biocompatibility information are of importance in regulatory approval.

7. Limitations and Future Research Directions

Nevertheless, this study had several limitations which should be mentioned regardless of its promising results. First, the analysis was mainly done by in vitro tests which cannot recreplicate the multifaceted physiological setup that is seen in vivo [19]. Issues like tissue contacts, enzyme action, immunological reactions and dynamic fluid flow can affect the degradation of implants and drug release differently compared to the results in controlled laboratory environments. Second, the polymers that were studied (although representative) were restricted to the most employed biodegradable materials. The new polymers with sophisticated functionalities were not investigated. Whereas it is also possible that the behaviour of complex therapeutics with higher molecular complexity is not entirely observed with the use of model small-molecule and peptide drugs.

Future studies are then encouraged to focus more on in vivo research studies to reinforce the release behaviour, biocompatibility, and efficacy of the future therapy in real physiological conditions. Further development of the advanced polymer systems such as stimuli-responsive, buffered, or multifunctional can be investigated to improve the regulation of release and stability of drugs [20]. Developing additive manufacturing methods to create personalised implant shapes may enable the customisation of the implant geometry, drug loading and or release profiles to patient-specific requirements. Additionally, clinical translation will be necessary with long-term safety studies and scalability tests.

8. Conclusion

8.1 Summary of Key Findings

This experiment proved that biodegradable polymeric implants could be used successfully as the platform of delivering small-molecule and peptide drugs over a long period of time. Findings verified that the polymer composition and method of fabricating implants were major factors that affected morphology, mechanical integrity, degradation behaviour, and release kinetics of the implants. Systems of polycaprolactone allowed a longer release and poly(lactic-co-glycolic acid) formulations facilitated faster release and sooner access to drugs.

8.2 Contribution to Sustained Drug Delivery Research

The results enhance the continued studies on the research on drug delivery by offering comparative evidence regarding the interactions between the polymer selection, the choice of processing strategy, and the type of drug used to achieve the desired results in terms of the performance of the implants. The study raises the issue of designing drugs-specific implants and not generic formulations because it is a compound that accommodates both small-molecule and peptide therapeutics in a single framework. The findings support the ability of biodegradable substances to surmount the constraints of traditional dosage forms such as frequent dosages and fluctuating bioavailability.

8.3 Overall Significance and Outlook

In sum, this study has highlighted the great promise of biodegradable polymers-based implants to be used as long-acting, multi-purpose drug delivery systems. Their ability to deliver on controlled release, do away with surgery, and enable patients to be adherent makes them worthy alternatives to other current treatments. The results indicate further development of the implant-based delivery of small-molecule and peptide drugs to enhance better patient-centred pharmacotherapy. Through integrating material science, pharmaceutical engineering, and drug delivery concepts within the work confirms the strategic potential of biodegradable implants in meeting unmet therapeutic needs and in driving sustained release technologies in advance of the modern healthcare systems in addition to providing a competitive reference framework on the way future academic research, industrial development may be conducted.

REFERENCE

[1] Wang Q, Yu X, Chen X, Gao J, Shi D, Shen Y, Tang J, He J, Li A, Yu L, Ding J. A facile composite strategy to prepare a biodegradable polymer based radiopaque raw material for “visualizable” biomedical implants. ACS Applied Materials & Interfaces. 2022 May 17;14(21):24197-212.

[2] Osi B, Khoder M, Al-Kinani AA, Alany RG. Pharmaceutical, biomedical and ophthalmic applications of biodegradable polymers (BDPs): literature and patent

review. Pharmaceutical development and technology. 2022 Mar 16;27(3):341-56.
[3] Kurowiak J, Klekiel T, Będziński R. Biodegradable polymers in biomedical applications: a review—developments, perspectives and future challenges. International journal of molecular sciences. 2023 Nov 29;24(23):16952.
[4] Oleksy M, Dynarowicz K, Aebisher D. Advances in biodegradable polymers and biomaterials for medical applications—a review. Molecules. 2023 Aug 24;28(17):6213.
[5] Magill E, Demartis S, Gavini E, Permana AD, Thakur RR, Adrianto MF, Waite D, Glover K, Picco CJ, Korelidou A, Detamornrat U. Solid implantable devices for sustained drug delivery. Advanced Drug Delivery Reviews. 2023 Aug 1;199:114950.
[6] Peers S, Montembault A, Ladaviere C. Chitosan hydrogels incorporating colloids for sustained drug delivery. Carbohydrate polymers. 2022 Jan 1;275:118689.
[7] Wu J, Shaidani S, Theodossiou SK, Hartzell EJ, Kaplan DL. Localized, on-demand, sustained drug delivery from biopolymer-based materials. Expert opinion on drug delivery. 2022 Oct 3;19(10):1317-35.
[8] Li Y, Ji T, Torre M, Shao R, Zheng Y, Wang D, Li X, Liu A, Zhang W, Deng X, Yan R. Aromatized liposomes for sustained drug delivery. Nature communications. 2023 Oct 20;14(1):6659.
[9] Almasi H, Jahanbakhsh Oskouie M, Saleh A. A review on techniques utilized for design of controlled release food active packaging. Critical reviews in food science and nutrition. 2021 Aug 22;61(15):2601-21.
[10] Vasile C, Baican M. Progresses in food packaging, food quality, and safety—controlled-release antioxidant and/or antimicrobial packaging. Molecules. 2021 Feb 26;26(5):1263.
[11] Lawrencia D, Wong SK, Low DY, Goh BH, Goh JK, Ruktanonchai UR, Soottitantawat A, Lee LH, Tang SY. Controlled release fertilizers: A review on coating materials and mechanism of release. Plants. 2021 Jan 26;10(2):238.
[12] Adepu S, Ramakrishna S. Controlled drug delivery systems: current status and future directions. Molecules. 2021 Sep 29;26(19):5905.
[13] Yamaguchi H, Hsu JM, Yang WH, Hung MC. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nature Reviews Clinical Oncology. 2022 May;19(5):287-305.
[14] Qiu S, Cai Y, Yao H, Lin C, Xie Y, Tang S, Zhang A. Small molecule metabolites: discovery of biomarkers and therapeutic targets. Signal Transduction and Targeted Therapy. 2023 Mar 20;8(1):132.
[15] Tian D, Liu Y, Liang C, Xin L, Xie X, Zhang D, Wan M, Li H, Fu X, Liu H, Cao W. An update review of emerging small-molecule therapeutic options for COVID-19. Biomedicine & Pharmacotherapy. 2021 May 1;137:111313.
[16] Wang L, Kumar R, Pavlov PF, Winblad B. Small molecule therapeutics for tauopathy in Alzheimer's disease: walking on the path of most resistance. European journal of medicinal chemistry. 2021 Jan 1;209:112915.
[17] Zhu YS, Tang K, Lv J. Peptide–drug conjugate-based novel molecular drug delivery system in cancer. Trends in pharmacological sciences. 2021 Oct 1;42(10):857-69.
[18] Berillo D, Yeskendir A, Zharkinbekov Z, Raziyeva K, Saparov A. Peptide-based drug delivery systems. Medicina. 2021 Nov 5;57(11):1209.
[19] Asfour MH. Advanced trends in protein and peptide drug delivery: a special emphasis on aquasomes and microneedles techniques. Drug delivery and translational research. 2021 Feb;11(1):1-23.
[20] Charan N. Protein and peptide drug delivery. Smart Drug Delivery. 2022 Jul 6;12:39..